Application/NN
of/IN
Cancer/NN
Genomics/NNS
to/TO
Solve/VB
Unmet/NN
Clinical/JJ
Needs/NNS
./.
====================
The/DT
large/JJ
amount/NN
of/IN
data/NNS
on/IN
cancer/NN
genome/NN
research/NN
has/VBZ
contributed/VBN
to/TO
our/PRP$
understanding/NN
of/IN
cancer/NN
biology/NN
./.
====================
Indeed/RB
,/,
the/DT
genomics/NNS
approach/NN
has/VBZ
a/DT
strong/JJ
advantage/NN
for/IN
analyzing/VBG
multi-factorial/JJ
and/CC
complicated/VBD
problems/NNS
,/,
such/JJ
as/IN
cancer/NN
./.
====================
It/PRP
is/VBZ
time/NN
to/TO
think/VB
about/RB
the/DT
actual/JJ
usage/NN
of/IN
cancer/NN
genomics/NNS
in/IN
the/DT
clinical/JJ
field/NN
./.
====================
The/DT
clinical/JJ
cancer/NN
field/NN
has/VBZ
lots/NNS
of/IN
unmet/JJ
needs/VBZ
in/IN
the/DT
management/NN
of/IN
cancer/NN
patients/NNS
,/,
which/WDT
has/VBZ
been/VBN
defined/VBN
in/IN
the/DT
pre-genomic/JJ
era/NNS
./.
====================
Unmet/IN
clinical/JJ
needs/VBZ
are/VBP
not/RB
well/RB
known/VBN
to/TO
bioinformaticians/NNS
and/CC
even/RB
non-clinician/JJ
cancer/NN
scientists/NNS
./.
====================
A/DT
personalized/VBN
approach/NN
in/IN
the/DT
clinical/JJ
field/NN
will/MD
bring/VBG
potential/JJ
additional/JJ
challenges/NNS
to/TO
cancer/NN
genomics/NNS
,/,
because/IN
most/JJS
data/NNS
to/TO
now/RB
have/VBP
been/VBN
population-based/VBN
rather/RB
than/IN
individual-based/VBN
./.
====================
We/PRP
can/MD
maximize/VB
the/DT
use/NN
of/IN
cancer/NN
genomics/NNS
in/IN
the/DT
clinical/JJ
field/NN
if/IN
cancer/NN
scientists/NNS
,/,
bioinformaticians/NNS
,/,
and/CC
clinicians/NNS
think/VBP
and/CC
work/NN
together/RB
in/IN
solving/JJ
unmet/IN
clinical/JJ
needs/VBZ
./.
====================
In/IN
this/DT
review/NN
,/,
we/PRP
present/VBP
one/CD
imaginary/JJ
case/NN
of/IN
a/DT
cancer/NN
patient/NN
,/,
with/IN
which/WDT
we/PRP
can/MD
think/VB
about/RB
unmet/IN
clinical/JJ
needs/VBZ
to/TO
solve/VB
with/IN
cancer/NN
genomics/NNS
in/IN
the/DT
diagnosis/NN
,/,
prediction/NN
of/IN
prognosis/NN
,/,
monitoring/VBG
the/DT
status/NN
of/IN
cancer/NN
,/,
and/CC
personalized/VBD
treatment/NN
decision/NN
./.
====================
Despite/IN
the/DT
explosive/JJ
increase/VBP
in/IN
cancer/NN
genomics/NNS
data/NNS
,/,
the/DT
actual/JJ
application/NN
of/IN
genomics/NNS
data/NNS
and/CC
approach/NN
to/TO
clinics/NNS
offers/VBZ
big/NN
challenges/NNS
[/(
1/CD
,/,
2/CD
]/)
./.
====================
The/DT
main/JJ
reason/NN
for/IN
the/DT
delay/NN
in/IN
the/DT
application/NN
to/TO
clinics/NNS
is/VBZ
non-connectivity/JJ
between/IN
bioinformaticians/NNS
,/,
non-clinical/JJ
scientists/NNS
,/,
and/CC
clinicians/NNS
./.
====================
Clinicians/NNS
are/VBP
not/RB
confident/JJ
in/IN
how/WRB
much/RB
additional/JJ
information/NN
might/MD
be/VB
given/VBN
through/IN
genomics/NNS
technology/NN
compared/VBN
to/TO
conventional/JJ
tools/NNS
,/,
and/CC
non-clinical/JJ
scientists/NNS
and/CC
bioinformaticians/NNS
are/VBP
not/RB
aware/VB
of/IN
what/WP
clinical/JJ
problems/NNS
should/MD
be/VB
solved/VBN
with/IN
priority/NN
./.
====================
Cancer/NN
clinicians/NNS
expect/VB
novel/JJ
diagnostic/JJ
,/,
prognostic/JJ
,/,
and/CC
therapeutic/JJ
values/NNS
of/IN
this/DT
new/JJ
technology/NN
[/(
1/CD
]/)
./.
====================
Now/RB
,/,
the/DT
clinical/JJ
field/NN
is/VBZ
aware/JJ
that/DT
multiple/JJ
assays/NNS
using/VBG
next-generation/JJ
sequencing/NN
(/(
NGS/NN
)/)
has/VBZ
some/DT
advantage/NN
over/IN
single/JJ
genetic/JJ
tests/NNS
[/(
1/CD
,/,
3/CD
]/)
./.
====================
A/DT
recent/JJ
cancer/NN
guideline/NN
from/IN
the/DT
National/JJ
Comprehensive/JJ
Cancer/NN
Network/NN
(/(
NCCN/NN
)/)
pointed/VBD
out/RP
that/DT
epidermal/JJ
growth/NN
factor/NN
receptor/NN
(/(
EGFR/NN
)/)
and/or/CC
anaplastic/JJ
lymphoma/NN
kinase/NN
(/(
ALK/NN
)/)
testing/VBG
should/MD
be/VB
conducted/VBN
as/IN
part/NN
of/IN
multiplex/NGS/JJ
in/IN
non-small-cell/JJ
lung/NN
cancer/NN
(/(
NSCLC/NN
)/)
[/(
4/CD
]/)
./.
====================
The/DT
feasibility/NN
of/IN
an/DT
NGS/NN
diagnostic/JJ
platform/NN
at/IN
cancer/NN
clinics/NNS
was/VBD
validated/VBN
by/IN
cancer/NN
centers/NNS
in/IN
the/DT
United/JJ
States/NNS
[/(
5/CD
]/)
and/CC
Europe/NN
[/(
6/CD
]/)
./.
====================
One/CD
platform/NN
showed/VBD
that/IN
potential/JJ
hurdles/NNS
,/,
time/NN
,/,
cost/RB
,/,
purity/NN
,/,
and/CC
ethical/JJ
problems/VBZ
could/MD
be/VB
overcome/VBN
in/IN
implementing/VBG
NGS/NN
using/VBG
low-coverage/JJ
whole-genome/DT
sequencing/NN
,/,
whole-exome/DT
sequencing/NN
(/(
WES/NNS
)/)
,/,
and/CC
whole-transcriptome/JJ
sequencing/NN
[/(
5/CD
]/)
./.
====================
Another/DT
platform/NN
sequenced/VBN
clinical/JJ
samples/NNS
,/,
including/VBG
formalin-fixed/JJ
,/,
paraffin-embedded/JJ
ones/NNS
,/,
and/CC
showed/VBD
that/IN
this/DT
approach/NN
is/VBZ
practical/JJ
and/CC
can/MD
give/VB
some/DT
benefits/VBZ
to/TO
the/DT
patients/NNS
with/IN
lung/NN
cancer/NN
[/(
6/CD
]/)
./.
====================
The/DT
WES/NN
approach/NN
in/IN
Mendelian/JJ
disorders/NNS
showed/VBD
that/IN
~25/CD
%/NN
of/IN
sequencing/NN
can/MD
give/VB
a/DT
specific/JJ
diagnosis/NN
based/VBN
on/IN
the/DT
germline/NN
genetic/JJ
make-up/VBP
from/IN
the/DT
data/NNS
of/IN
250/CD
probands/NNS
,/,
mostly/RB
consisting/VBG
of/IN
neurological/JJ
phenotypes/NNS
in/IN
real/JJ
practice/NN
[/(
7/CD
]/)
./.
====================
The/DT
clinical/JJ
application/NN
of/IN
cancer/NN
genomics/NNS
should/MD
be/VB
considered/VBN
in/IN
the/DT
context/NN
of/IN
unmet/JJ
clinical/JJ
needs/VBZ
to/TO
maximize/VB
the/DT
value/NN
of/IN
this/DT
novel/JJ
paradigm/NN
./.
====================
Here/RB
,/,
we/PRP
dealt/VBP
with/IN
the/DT
potential/JJ
clinical/JJ
application/NN
of/IN
cancer/NN
genomics/NNS
in/IN
the/DT
aspect/NN
of/IN
practical/JJ
management/NN
of/IN
cancer/NN
patients/NNS
,/,
along/IN
with/IN
a/DT
clinical/JJ
scenario/NN
covering/VBG
the/DT
whole/JJ
course/NN
of/IN
cancer/NN
management/NN
./.
====================
We/PRP
overviewed/VBD
the/DT
potential/JJ
of/IN
cancer/NN
genomics/NNS
in/IN
the/DT
context/NN
of/IN
real/JJ
cancer/NN
practice/NN
through/IN
this/DT
approach/NN
./.
====================
A/DT
64-year-old/JJ
male/JJ
presented/VBN
with/IN
a/DT
cough/JJ
since/IN
2/CD
months/NNS
ago/NN
./.
====================
He/RB
quit/RB
smoking/NN
10/CD
years/NNS
ago/NN
and/CC
had/VBD
smoked/VBN
an/DT
average/NN
of/IN
one/CD
pack/NN
per/FW
day/NN
for/IN
30/CD
years/NNS
./.
====================
He/RB
had/VBD
regular/JJ
check-ups/NNS
every/RB
year/NN
and/CC
had/VBD
the/DT
last/JJ
check-up/NN
with/IN
no/DT
abnormality/NN
6/CD
months/NNS
ago/RB
./.
====================
His/NN
chest/VBP
roentgenogram/NN
showed/VBD
a/DT
mass/NN
shadow/NN
in/IN
the/DT
lung/NN
./.
====================
He/RB
got/NN
a/DT
percutaneous/JJ
needle/NN
aspiration/NN
(/(
PCNA/NN
)/)
and/CC
biopsy/NN
but/CC
did/VBD
not/RB
have/VB
any/DT
tumor/NN
cells/NNS
./.
====================
He/RB
repeated/VBN
the/DT
PCNA/NN
and/CC
biopsy/NN
but/CC
developed/VBD
pneumothorax/NN
(/(
air/NN
leakage/NN
from/IN
lung/NN
)/)
related/JJ
to/TO
the/DT
diagnostic/JJ
procedure/NN
./.
====================
His/NN
second/JJ
biopsy/NN
showed/VBD
some/DT
malignant/JJ
cells/NNS
,/,
suggestive/JJ
of/IN
adenocarcinoma/NN
./.
====================
After/IN
a/DT
staging/JJ
work-up/NN
with/IN
a/DT
computed/JJ
tomography/NN
(/(
CT/NN
)/)
scan/VBP
,/,
positron-emission/NN
tomography/NN
(/(
PET/NN
)/)
scan/VBP
,/,
brain/NN
magnetic/JJ
resonance/NN
imaging/VBG
scan/NN
,/,
and/CC
bronchoscopy/NN
,/,
his/DT
tumor/NN
was/VBD
revealed/VBN
as/IN
T2N0/CD
clinical/JJ
stage/NN
./.
====================
He/RB
got/NN
a/DT
surgery/NN
based/VBN
on/IN
the/DT
result/NN
of/IN
the/DT
pathology/NN
and/CC
staging/NN
work-up/NN
./.
====================
In/IN
this/DT
situation/NN
,/,
we/PRP
face/VBP
unmet/JJ
clinical/JJ
needs/VBZ
of/IN
early/JJ
cancer/NN
diagnosis/NN
./.
====================
He/RB
was/VBD
diagnosed/VBN
with/IN
symptoms/NNS
related/JJ
to/TO
the/DT
cancer/NN
,/,
despite/IN
his/DT
regular/JJ
check-up/NN
./.
====================
If/IN
we/PRP
detect/VBP
his/NN
malignancy/NN
before/IN
the/DT
symptoms/NNS
,/,
we/PRP
can/MD
get/VB
a/DT
better/RBR
result/NN
compared/VBN
with/IN
the/DT
symptomatic/JJ
case/NN
[/(
8/CD
]/)
./.
====================
This/DT
imaginary/JJ
patient/NN
was/VBD
diagnosed/VBN
with/IN
operable/JJ
cancer/NN
,/,
but/CC
as/IN
many/JJ
as/IN
60/CD
%/NN
to/TO
70/CD
%/NN
of/IN
lung/NN
cancer/NN
patients/NNS
are/VBP
diagnosed/VBN
with/IN
inoperable/JJ
,/,
advanced/JJ
disease/NN
[/(
9/CD
]/)
./.
====================
To/TO
diagnose/VB
the/DT
cancer/NN
sooner/RB
,/,
screening/NN
procedures/NNS
have/VBP
been/VBN
studied/VBN
extensively/RB
in/IN
the/DT
clinical/JJ
field/NN
./.
====================
Lots/NNS
of/IN
trials/NNS
failed/VBD
to/TO
show/VB
an/DT
actual/JJ
benefit/IN
of/IN
screening/VBG
strategy/NN
in/IN
lung/NN
cancer/NN
[/(
10/CD
,/,
11/CD
]/)
,/,
but/CC
recently/RB
,/,
a/DT
screening/NN
trial/JJ
using/VBG
low-dose/JJ
chest/VBP
CT/NN
of/IN
lung/NN
cancer/NN
was/VBD
proven/VBN
to/TO
be/VB
successful/JJ
[/(
8/CD
]/)
./.
====================
Low-dose/JJ
chest/VBP
CT/NN
reduced/VBD
the/DT
mortality/NN
from/IN
lung/NN
cancer/NN
through/IN
early/JJ
detection/NN
in/IN
people/JJ
with/IN
a/DT
history/JJ
of/IN
at/IN
least/JJS
30/CD
pack-years/NNS
of/IN
smoking/NN
./.
====================
Despite/IN
this/DT
good/JJ
approach/NN
to/TO
detect/VB
early/JJ
lung/NN
cancer/NN
,/,
the/DT
reduction/NN
of/IN
mortality/NN
is/VBZ
20/CD
%/NN
[/(
8/CD
]/)
./.
====================
This/DT
advantage/NN
should/MD
be/VB
counterbalanced/VBN
with/IN
the/DT
potential/JJ
harmful/JJ
effects/NNS
of/IN
radiation/NN
exposure/NN
or/CC
false/VBP
positivity/NN
[/(
12/CD
]/)
./.
====================
One/CD
important/JJ
usage/NN
of/IN
genomics/NNS
should/MD
be/VB
early/JJ
detection/NN
./.
====================
Many/JJ
biomarkers/NNS
were/VBD
investigated/VBN
for/IN
the/DT
early/JJ
detection/NN
of/IN
lung/NN
cancer-for/IN
example/NN
,/,
circulating/VBG
tumor/NN
DNA/NN
and/CC
RNA/NN
[/(
13/CD
]/)
./.
====================
But/CC
,/,
false/VBP
positivity/NN
and/CC
false/VBP
negativity/NN
of/IN
single/JJ
tests/NNS
prevent/VBP
these/DT
tests/NNS
from/IN
clinical/JJ
usage/NN
./.
====================
If/IN
we/PRP
use/VBP
multiple/JJ
biomarkers/NNS
using/VBG
cancer/NN
genomics/NNS
for/IN
the/DT
detection/NN
of/IN
early/JJ
cancer/NN
,/,
the/DT
false/NN
positives/VBZ
and/CC
negatives/NNS
could/MD
be/VB
reduced/VBN
to/TO
the/DT
level/NN
of/IN
clinical/JJ
usage/NN
./.
====================
Another/DT
effective/JJ
approach/NN
of/IN
early/JJ
diagnosis/NN
of/IN
cancer/NN
is/VBZ
to/TO
select/VB
a/DT
high-risk/JJ
population/NN
for/IN
screening/NN
tests/NNS
./.
====================
Many/JJ
genome-wide/NN
association/NN
studies/NNS
identified/VBD
some/DT
germline/NN
single-nucleotide/JJ
polymorphism/NN
(/(
SNPs/NNS
)/)
that/WDT
are/VBP
associated/VBN
with/IN
the/DT
risk/NN
of/IN
cancers/NNS
[/(
14-16/CD
]/)
,/,
and/CC
these/DT
findings/NNS
suggested/VBD
important/JJ
potential/JJ
germline/NN
markers/NNS
for/IN
the/DT
definition/NN
of/IN
high-risk/JJ
populations/NNS
./.
====================
Dr./NNP
Mardis/NN
told/JJ
the/DT
case/NN
of/IN
Mike/JJ
Snyder/NN
as/IN
an/DT
example/NN
of/IN
an/DT
actual/JJ
application/NN
of/IN
a/DT
germline/NN
genome/NN
test/NN
[/(
17/CD
]/)
./.
====================
He/RB
sequenced/VBN
his/DT
own/JJ
genome/NN
and/CC
found/VBD
a/DT
higher/JJR
risk/NN
of/IN
type/NN
2/CD
diabetes/NNS
;/:
since/IN
that/DT
time/NN
,/,
he/RB
checked/VBD
his/DT
glucose/NN
level/NN
regularly/RB
,/,
and/CC
he/RB
detected/VBN
high/JJ
glucose/NN
levels/NNS
at/IN
the/DT
very/RB
beginning/VBG
./.
====================
After/IN
that/DT
,/,
he/RB
exercised/VBD
regularly/RB
and/CC
returned/VBD
to/TO
normal/JJ
glucose/NN
levels/NNS
./.
====================
The/DT
concept/NN
of/IN
early/JJ
diagnosis/NN
,/,
like/IN
the/DT
story/JJ
of/IN
Mike/JJ
Snyder/NN
,/,
can/MD
be/VB
applied/VBN
to/TO
the/DT
early/JJ
detection/NN
of/IN
cancer/NN
,/,
too/RB
./.
====================
If/IN
we/PRP
define/VBP
a/DT
high-risk/JJ
population/NN
with/IN
germline/NN
genetic/JJ
tests/NNS
,/,
we/PRP
could/MD
focus/VB
on/IN
the/DT
use/NN
of/IN
screening/VBG
tests/NNS
in/IN
this/DT
population/NN
./.
====================
This/DT
approach/NN
will/MD
also/RB
save/VBP
money/NN
on/IN
screening/NN
tests/NNS
for/IN
the/DT
whole/JJ
population/NN
./.
====================
This/DT
patient/NN
had/VBD
a/DT
bad/NN
experience/VBP
of/IN
pneumothorax/NN
./.
====================
This/DT
complication/NN
gives/VBZ
pain/NN
and/CC
discomfort/JJ
of/IN
the/DT
sensation/NN
of/IN
dyspnea/NN
,/,
prolongs/VBZ
the/DT
period/NN
of/IN
admission/NN
,/,
and/CC
increases/VBZ
the/DT
cost/JJ
of/IN
cancer/NN
management/NN
./.
====================
This/DT
problem/NN
originated/VBN
from/IN
the/DT
invasive/JJ
nature/NN
of/IN
the/DT
diagnostic/JJ
procedure-PCNA/JJ
and/CC
biopsy/NN
using/VBG
a/DT
needle/NN
,/,
moving/VBG
back/RB
and/CC
forth/IN
through/IN
the/DT
patient/NN
's/POS
fragile/NN
lung/NN
tissue/NN
./.
====================
New/NN
diagnostic/JJ
tools/NNS
using/VBG
cancer/NN
genomics-for/IN
example/NN
,/,
identification/NN
of/IN
cancer-specific/JJ
genetic/JJ
alterations/NNS
from/IN
circulating/VBG
tumor/NN
DNA-can/NN
avoid/JJ
this/DT
type/NN
of/IN
complication/NN
from/IN
invasive/JJ
procedures/NNS
./.
====================
One/CD
pioneering/VBG
study/NN
showed/VBD
that/IN
circulating/VBG
tumor/NN
DNA/NN
could/MD
be/VB
combined/VBN
with/IN
genomic/JJ
technology/NN
to/TO
diagnose/VB
and/CC
monitor/VB
the/DT
status/NN
of/IN
cancer/NN
very/RB
safely/RB
[/(
18/CD
]/)
./.
====================
He/RB
underwent/JJ
surgery/NN
performed/VBN
by/IN
thoracic/JJ
surgeons/NNS
./.
====================
His/NN
final/JJ
pathological/JJ
diagnosis/NN
was/VBD
adenocarcinoma/NN
and/CC
revealed/VBD
the/DT
involvement/NN
of/IN
some/DT
mediastinal/JJ
lymph/NN
nodes/NNS
;/:
therefore/RB
,/,
the/DT
final/JJ
pathological/JJ
stage/NN
was/VBD
T2N2/NN
,/,
IIIA/NN
./.
====================
This/DT
stage/NN
required/VBN
adjuvant/JJ
chemotherapy/NN
,/,
and/CC
he/RB
was/VBD
referred/VBN
to/TO
the/DT
department/JJ
of/IN
medical/JJ
oncology/NN
./.
====================
A/DT
medical/JJ
oncologist/NN
prescribed/VBN
adjuvant/JJ
chemotherapy-a/NN
navelbine/NN
and/CC
cisplatin/NN
regimen/NNS
(/(
NP/NN
)/)
for/IN
4/CD
cycles/NNS
./.
====================
NP/NN
4/CD
cycles/NNS
has/VBZ
been/VBN
prescribed/VBN
to/TO
patients/NNS
with/IN
high-risk/JJ
clinical/JJ
stage/NN
IB/NN
,/,
IIA/NN
,/,
IIB/NN
,/,
IIIA/NN
,/,
and/CC
IIIB/NN
,/,
regardless/RB
of/IN
other/JJ
clinicopathological/JJ
factors/NNS
./.
====================
The/DT
actual/JJ
benefit/VB
from/IN
this/DT
treatment/NN
is/VBZ
only/RB
a/DT
4/CD
%/NN
long-term/JJ
survival/NN
advantage/NN
,/,
with/IN
some/DT
hematological/JJ
and/CC
non-hematological/JJ
toxicities/NNS
[/(
19/CD
,/,
20/CD
]/)
./.
====================
The/DT
way/NN
to/TO
improve/VB
the/DT
risk-to-benefit/NN
ratio/NN
of/IN
adjuvant/JJ
treatment/NN
is/VBZ
further/RBR
selection/NN
of/IN
a/DT
patient/NN
population/NN
that/WDT
could/MD
benefit/VB
from/IN
this/DT
treatment/NN
./.
====================
Stage-based/JJ
risk/NN
calculation-the/DT
current/JJ
practice-/NN
can/MD
not/RB
predict/VB
an/DT
accurate/JJ
risk/NN
of/IN
relapse/NN
and/CC
attenuates/NNS
the/DT
value/NN
of/IN
adjuvant/JJ
treatment/NN
./.
====================
Single/JJ
patient-based/VBN
risk/NN
calculation/NN
should/MD
be/VB
done/VBN
to/TO
identify/VB
the/DT
adequate/NN
patients/NNS
for/IN
adjuvant/JJ
treatment/NN
./.
====================
Cancer/NN
genomics/NNS
will/MD
provide/VB
useful/JJ
tools/NNS
for/IN
a/DT
single/JJ
patient-based/JJ
risk/NN
calculation/NN
model/NN
./.
====================
This/DT
personalized/VBD
adjuvant/JJ
model/NN
will/MD
definitely/RB
increase/VBP
the/DT
proportion/NN
of/IN
patients/NNS
who/WP
benefit/VBP
from/IN
it/PRP
./.
====================
There/EX
are/VBP
also/RB
clinical/JJ
needs/VBZ
of/IN
prognosis/NN
prediction/NN
even/RB
before/IN
surgery/NN
./.
====================
Surgical/JJ
management/NN
of/IN
stage/NN
IIIA/NN
is/VBZ
controversial/JJ
./.
====================
If/IN
he/RB
had/VBD
been/VBN
diagnosed/VBN
as/IN
stage/NN
IIIA/NN
preoperatively/RB
,/,
he/RB
might/MD
have/VBP
chosen/NN
a/DT
no-surgery/RB
option/NN
,/,
such/JJ
as/IN
concurrent/JJ
chemoradiation/NN
,/,
because/IN
no/DT
definite/JJ
benefit/IN
of/IN
surgery/NN
was/VBD
demonstrated/VBN
until/IN
now/RB
,/,
although/IN
this/DT
is/VBZ
controversial/JJ
[/(
21/CD
,/,
22/CD
]/)
./.
====================
We/PRP
have/VBP
relatively/RB
sensitive/JJ
diagnostic/JJ
methods/NNS
,/,
such/JJ
as/IN
CT/NN
,/,
PET/NN
,/,
and/CC
endobronchial/JJ
ultrasonography/NN
,/,
but/CC
the/DT
sensitivity/NN
and/CC
specificity/NN
are/VBP
still/RB
not/RB
perfect/VB
./.
====================
One/CD
focus/NN
of/IN
genomics/NNS
technology/NN
should/MD
be/VB
a/DT
more/RBR
accurate/JJ
prognosis/NN
preoperatively/RB
,/,
in/IN
addition/NN
to/TO
postoperatively/RB
./.
====================
Prediction/NN
issues/NNS
in/IN
cancer/NN
patients/NNS
are/VBP
not/RB
limited/JJ
to/TO
survival/NN
,/,
recurrence/NN
,/,
and/CC
response/NN
to/TO
specific/JJ
treatment/NN
./.
====================
The/DT
goal/NN
of/IN
cancer/NN
care/NN
is/VBZ
improvement/JJ
of/IN
survival/NN
and/CC
,/,
more/RBR
importantly/RB
,/,
quality/NN
of/IN
life/NN
./.
====================
Predictive/JJ
markers/NNS
of/IN
bone/NN
metastasis/NN
or/CC
bone-related/JJ
events/NNS
,/,
such/JJ
as/IN
fracture/NN
or/CC
paralysis/NN
,/,
are/VBP
very/RB
important/JJ
to/TO
improve/VB
the/DT
quality/NN
of/IN
life/NN
in/IN
cancer/NN
patients/NNS
./.
====================
We/PRP
have/VBP
no/DT
clinically/RB
validated/VBN
markers/NNS
to/TO
predict/VB
these/DT
events/NNS
[/(
23/CD
]/)
./.
====================
An/DT
unbiased/JJ
approach/NN
is/VBZ
needed/VBN
to/TO
discover/JJ
good/JJ
biomarker/NN
for/IN
these/DT
events/NNS
,/,
because/IN
we/PRP
have/VBP
very/RB
limited/JJ
clues/NNS
to/TO
dig/NN
into/IN
these/DT
problems/NNS
./.
====================
The/DT
most/JJS
important/JJ
advantage/NN
of/IN
genomics/NNS
approach/NN
is/VBZ
that/DT
is/VBZ
``/CD
unbiased/JJ
''/CD
with/IN
regard/NN
to/TO
any/DT
hypotheses/NNS
or/CC
theories/NNS
./.
====================
That/DT
is/VBZ
why/WRB
clinical/JJ
problems/NNS
with/IN
low-depth/JJ
knowledge/NN
are/VBP
a/DT
good/JJ
candidate/NN
for/IN
the/DT
application/NN
of/IN
cancer/NN
genomics/NNS
./.
====================
The/DT
connection/NN
between/IN
clinicians/NNS
and/CC
genomic/JJ
scientists/NNS
can/MD
facilitate/VB
the/DT
development/NN
of/IN
clinical/JJ
problems/NNS
that/DT
are/VBP
solved/VBN
with/IN
a/DT
genomic/JJ
approach/NN
./.
====================
He/RB
got/NN
4/CD
cycles/NNS
of/IN
adjuvant/JJ
chemotherapy/NN
and/CC
then/RB
followed/VBN
up/IN
regularly/RB
with/IN
a/DT
physical/JJ
examination/NN
,/,
blood/NN
test/NN
,/,
CT/NN
scan/NN
,/,
and/or/CC
PET/NN
scan/NN
./.
====================
At/IN
6/CD
months/NNS
since/IN
the/DT
completion/NN
of/IN
adjuvant/JJ
chemotherapy/NN
,/,
he/RB
presented/VBN
with/IN
right-side/JJ
chest/VBP
pain/NN
,/,
and/CC
his/NN
CT/NN
scan/NN
showed/VBD
tumor/NN
relapse/NN
in/IN
the/DT
right/JJ
lung/NN
and/CC
pleura/NN
./.
====================
He/RB
planned/JJ
systemic/JJ
anticancer/JJ
treatment/NN
for/IN
life/NN
prolongation/NN
and/CC
palliation/NN
of/IN
symptom/JJ
,/,
not/RB
curative/JJ
./.
====================
The/DT
role/NN
of/IN
CT/NN
scan/NN
and/or/CC
PET/NN
scan/NN
is/VBZ
not/RB
defined/VBN
[/(
24/CD
]/)
,/,
but/CC
many/JJ
clinicians/NNS
use/NN
this/DT
high-cost/JJ
image/NN
for/IN
monitoring/VBG
relapse/NN
./.
====================
The/DT
reason/NN
for/IN
the/DT
popular/JJ
use/NN
of/IN
this/DT
high-cost/JJ
image/NN
is/VBZ
that/DT
there/EX
is/VBZ
no/DT
other/JJ
alternative/JJ
of/IN
monitoring/VBG
cancer/NN
status/NN
./.
====================
Recent/JJ
studies/NNS
showed/VBD
the/DT
possibility/NN
of/IN
circulating/VBG
tumor/NN
cell/NN
and/CC
cell-free/JJ
DNA/NN
as/IN
a/DT
tool/NN
for/IN
monitoring/VBG
tumor/NN
status/NN
[/(
18/CD
,/,
25/CD
]/)
./.
====================
Cancer/NN
genomics/NNS
enables/VBZ
circulating/VBG
tumor/NN
cell/NN
or/CC
cell-free/JJ
DNA/NN
to/TO
detect/VB
relapse/NN
earlier/RBR
than/IN
image/NN
findings/NNS
or/CC
tumor/NN
markers/NNS
./.
====================
The/DT
delicate/JJ
delineation/NN
of/IN
circulating/VBG
DNA/NN
with/IN
NGS/NN
technologies/NNS
is/VBZ
an/DT
essential/JJ
part/NN
of/IN
this/DT
success/NN
story/JJ
./.
====================
No/DT
tool/NN
is/VBZ
available/JJ
with/IN
a/DT
definite/JJ
clinical/JJ
benefit/NN
for/IN
the/DT
monitoring/JJ
of/IN
cancer/NN
;/:
therefore/RB
,/,
we/PRP
absolutely/RB
need/VBD
new/JJ
,/,
non-invasive/JJ
tools/NNS
for/IN
it/PRP
./.
====================
Because/IN
it/PRP
takes/VBZ
at/IN
least/JJS
several/JJ
years/NNS
to/TO
prove/VB
the/DT
benefit/NN
of/IN
monitoring/VBG
,/,
we/PRP
should/MD
start/VB
a/DT
well-designed/JJ
prospective/JJ
study/NN
using/VBG
cancer/NN
genomics/NNS
to/TO
prove/VB
it/PRP
as/IN
soon/RB
as/IN
possible/JJ
./.
====================
The/DT
medical/JJ
oncologist/RB
who/WP
was/VBD
in/IN
charge/JJ
of/IN
him/JJ
tested/VBN
for/IN
EGFR/NN
mutation/NN
and/CC
ALK/NN
by/IN
fluorescence/NN
in/FW
situ/FW
hybridization/NN
to/TO
see/VB
rearrangements/NNS
of/IN
ALK/NN
./.
====================
Tests/NNS
showed/VBD
no/DT
EGFR/NN
mutation/NN
and/CC
no/DT
ALK/NN
translocation/NN
./.
====================
He/RB
chose/NN
cytotoxic/JJ
chemotherapy/NN
with/IN
pemetrexed/JJ
and/CC
cisplatin/NN
according/VBG
to/TO
the/DT
double-negative/JJ
results/NNS
of/IN
the/DT
EGFR/NN
and/CC
ALK/NN
tests/NNS
./.
====================
The/DT
ultimate/JJ
goal/NN
of/IN
the/DT
clinical/JJ
application/NN
of/IN
cancer/NN
genomics/NNS
should/MD
be/VB
therapeutics/NNS
./.
====================
There/EX
are/VBP
increasing/VBG
gene/NN
lists/NNS
for/IN
NSCLC/NN
that/DT
have/VBP
matching/VBG
targeted/VBN
agents/NNS
[/(
26/CD
,/,
27/CD
]/)
,/,
but/CC
many/JJ
patients/NNS
do/VBP
not/RB
have/VB
genetic/JJ
alterations/NNS
that/IN
can/MD
be/VB
a/DT
target/NN
./.
====================
Even/RB
for/IN
the/DT
same/JJ
type/NN
of/IN
cancer-for/JJ
example/NN
,/,
lung/NN
adenocarcinoma-the/DT
genetic/JJ
make-up/NN
is/VBZ
very/RB
heterogeneous/JJ
./.
====================
The/DT
accurate/JJ
definition/NN
of/IN
the/DT
genetic/JJ
make-up/NN
of/IN
each/DT
patient/NN
will/MD
be/VB
the/DT
first/JJ
step/NN
for/IN
personalized/VBN
medicine/NN
./.
====================
Many/JJ
target/NN
panels/NNS
have/VBP
been/VBN
developed/VBN
by/IN
many/JJ
vendors/NNS
and/CC
hospitals/NNS
for/IN
commercial/JJ
or/CC
non-commercial/JJ
use/NN
[/(
3/CD
]/)
,/,
but/CC
the/DT
usage/NN
is/VBZ
still/RB
very/RB
limited/JJ
./.
====================
As/IN
more/RBR
cancer/NN
genome/NN
data/NNS
are/VBP
available/JJ
[/(
28/CD
,/,
29/CD
]/)
,/,
the/DT
list/NN
of/IN
target/NN
panels/NNS
will/MD
increase/VB
and/CC
be/VB
specified/VBN
to/TO
tumor/NN
types/NNS
./.
====================
Now/RB
,/,
we/PRP
have/VBP
two/CD
targeted/VBN
agents/NNS
to/TO
prolong/VB
the/DT
survival/NN
of/IN
lung/NN
cancer/NN
patients/NNS
:/:
the/DT
EGFR/NN
tyrosine/NN
kinase/NN
inhibitor/NN
(/(
TKI/NN
)/)
erlotinib/NN
or/CC
gefitinib/JJ
for/IN
EGFR/NN
mutations/NNS
and/CC
the/DT
ALK/NN
TKI/NN
crizotinib/JJ
for/IN
ALK/NN
translocations/NNS
./.
====================
For/IN
this/DT
case/NN
,/,
there/EX
was/VBD
no/DT
targeted/VBN
agent/NN
,/,
because/IN
he/RB
did/VBD
not/RB
have/VB
EGFR/NN
or/CC
ALK/NN
alterations/NNS
./.
====================
Based/VBN
on/IN
the/DT
histology/NN
of/IN
his/DT
tumor/NN
,/,
he/RB
was/VBD
treated/VBN
with/IN
pemetrexed/JJ
and/CC
cisplatin/NN
[/(
30/CD
]/)
./.
====================
Despite/IN
the/DT
substantial/JJ
toxicity/NN
of/IN
cytotoxic/JJ
chemotherapy/NN
,/,
many/JJ
patients/NNS
are/VBP
prescribed/VBN
these/DT
drugs/NNS
with/IN
the/DT
individualized/VBN
possibility/NN
of/IN
this/DT
agent/NN
not/RB
known/VBN
./.
====================
This/DT
decision/NN
relies/VBZ
on/IN
population/NN
data/NNS
from/IN
large-scale/JJ
prospective/JJ
trials/NNS
./.
====================
Because/IN
clinical/JJ
trials/NNS
targeting/VBG
specific/JJ
genetic/JJ
alterations/NNS
are/VBP
increasing/VBG
,/,
the/DT
clinical/JJ
need/NN
for/IN
more/RBR
genetic/JJ
information/NN
is/VBZ
also/RB
increasing/VBG
[/(
31/CD
]/)
./.
====================
If/IN
the/DT
patient/NN
was/VBD
diagnosed/VBN
as/IN
stage/NN
IV/CD
initially/RB
,/,
the/DT
amount/NN
of/IN
tissue/NN
for/IN
genetic/JJ
testing/NN
is/VBZ
very/RB
limited/JJ
./.
====================
The/DT
amount/NN
of/IN
tissue/NN
is/VBZ
enough/IN
for/IN
2/CD
or/CC
3/CD
genetic/JJ
tests/NNS
./.
====================
For/IN
these/DT
patients/NNS
,/,
multiplexing/JJ
or/CC
NGS/NN
technologies/NNS
have/VBP
important/JJ
advantages/NNS
to/TO
overcome/VB
the/DT
limitation/NN
of/IN
tissue/NN
amounts/NNS
in/IN
the/DT
clinic/NN
./.
====================
This/DT
patient/NN
got/NN
adjuvant/JJ
chemotherapy/NN
with/IN
NP/NN
for/IN
4/CD
cycles/NNS
but/CC
progressed/VBD
6/CD
months/NNS
after/IN
the/DT
completion/NN
./.
====================
We/PRP
guess/VBP
that/DT
the/DT
patient/NN
did/VBD
not/RB
benefit/VB
from/IN
NP/NN
for/IN
4/CD
cycles/NNS
./.
====================
The/DT
usual/JJ
speculation/NN
is/VBZ
whether/IN
there/EX
is/VBZ
a/DT
better/RBR
way/NN
to/TO
choose/VB
adjuvant/JJ
treatment/NN
./.
====================
The/DT
way/NN
to/TO
increase/VB
the/DT
benefit/NN
of/IN
adjuvant/JJ
treatment/NN
could/MD
be/VB
the/DT
application/NN
of/IN
variable/JJ
adjuvant/JJ
treatment/NN
that/IN
is/VBZ
selected/VBN
from/IN
individualized/VBN
factors/NNS
./.
====================
Personalized/JJ
cancer/NN
genomic/JJ
analysis/NN
can/MD
show/VB
different/JJ
and/CC
private/JJ
profiles/NNS
of/IN
individual/JJ
cancers/NNS
,/,
and/CC
accumulation/NN
of/IN
these/DT
genomic/JJ
data/NNS
enables/VBZ
different/JJ
adjuvant/JJ
treatment/NN
strategies/NNS
for/IN
each/DT
patient/NN
./.
====================
Despite/IN
the/DT
theoretical/JJ
promise/VBP
of/IN
personalized/VBN
cancer/NN
genomic/JJ
analysis/NN
for/IN
the/DT
selection/NN
of/IN
the/DT
right/JJ
drug/NN
,/,
there/EX
are/VBP
few/JJ
examples/NNS
of/IN
this/DT
direct/JJ
application/NN
of/IN
cancer/NN
genomics/NNS
./.
====================
One/CD
of/IN
important/JJ
example/NN
is/VBZ
the/DT
story/JJ
of/IN
Lukas/NN
Wartman/JJ
,/,
a/DT
doctor/NN
at/IN
Washington/NN
University/NN
in/IN
St./FW
Louis/NN
[/(
32/CD
]/)
./.
====================
He/RB
suffered/VBD
from/IN
a/DT
second/JJ
relapse/NN
of/IN
acute/JJ
lymphoblastic/JJ
leukemia/NN
and/CC
sequenced/VBN
the/DT
tumor/NN
DNA/NN
and/CC
RNA/NN
./.
====================
He/RB
found/VBN
very/RB
high/JJ
expression/NN
of/IN
FLT3/NN
and/CC
then/RB
figured/VBD
out/RP
that/DT
sunitinib/NN
,/,
a/DT
kidney/NN
cancer/NN
drug/NN
,/,
could/MD
block/VB
tumor/NN
survival/NN
signals/NNS
./.
====================
Sunitinib/NN
induced/VBD
complete/JJ
remission/NN
in/IN
him/JJ
,/,
and/CC
thereafter/RB
,/,
he/RB
received/VBD
allogeneic/JJ
stem/NN
cell/NN
transplantation/NN
and/CC
is/VBZ
now/RB
in/IN
remission/NN
./.
====================
Another/DT
story/JJ
from/IN
the/DT
Fox/NN
Chase/NN
Cancer/NN
Center/NN
was/VBD
reported/VBN
on/IN
KIT/NN
mutations/NNS
from/IN
a/DT
pancreatic/JJ
neuroendocrine/NN
tumor/NN
[/(
33/CD
]/)
./.
====================
The/DT
patient/NN
had/VBD
an/DT
advanced/JJ
pancreatic/JJ
neuroendocrine/NN
tumor/NN
and/CC
sequenced/VBN
his/NN
tumor/NN
using/VBG
a/DT
cancer/NN
panel/NN
./.
====================
He/RB
had/VBD
a/DT
KIT/NN
mutation/NN
and/CC
was/VBD
treated/VBN
with/IN
imatinib/NN
,/,
a/DT
well-known/JJ
KIT/NN
inhibitor/NN
that/WDT
is/VBZ
not/RB
approved/JJ
for/IN
his/DT
tumor/NN
,/,
for/IN
more/RBR
than/IN
2/CD
years/NNS
./.
====================
If/IN
he/RB
had/VBD
been/VBN
in/IN
in/FW
routine/NN
practice/NN
without/IN
cancer/NN
panel/NN
sequencing/NN
,/,
he/RB
would/MD
have/VBP
died/VBN
without/IN
imatinib/NN
treatment/NN
./.
====================
A/DT
pharmacogenomic/JJ
approach/NN
could/MD
be/VB
used/VBN
to/TO
minimize/VB
toxicity/NN
to/TO
cancer/NN
treatment/NN
,/,
too/RB
./.
====================
In/IN
this/DT
case/NN
,/,
we/PRP
usually/RB
see/VB
germline/NN
SNP/NN
data/NNS
./.
====================
Some/DT
germline/NN
SNPs/NNS
are/VBP
already/RB
known/VBN
to/TO
predict/VB
erratic/JJ
side/JJ
effects/NNS
to/TO
specific/JJ
drugs/NNS
./.
====================
One/CD
example/NN
is/VBZ
the/DT
UGT1A1/NN
germline/NN
polymorphism/NN
for/IN
the/DT
metabolism/NN
and/CC
toxicity/NN
of/IN
irinotecan/JJ
./.
====================
If/IN
the/DT
patient/NN
has/VBZ
a/DT
homozygous/JJ
polymorphism/NN
in/IN
the/DT
UGT1A1/NN
gene-the/DT
*28/CD
variant-he/DT
should/MD
be/VB
prescribed/VBN
with/IN
a/DT
dose/NN
reduction/NN
to/TO
avoid/VB
severe/JJ
,/,
sometimes/RB
fatal/JJ
,/,
toxicity/NN
from/IN
irinotecan/JJ
./.
====================
A/DT
genomic/JJ
approach/NN
is/VBZ
required/VBN
to/TO
properly/RB
assess/VB
pharmacogenomics/NNS
in/IN
association/NN
with/IN
drug/NN
toxicity/NN
./.
====================
A/DT
commercial/JJ
chip/NN
,/,
the/DT
Affymetric/JJ
DMET/NN
chip/NN
,/,
covers/VBZ
25-32/CD
%/NN
of/IN
genes/NNS
of/IN
pharmacogenomics/NNS
,/,
and/CC
it/PRP
is/VBZ
an/DT
important/JJ
question/NN
whether/IN
more/RBR
coverage/JJ
with/IN
WES/NN
will/MD
be/VB
more/RBR
beneficial/JJ
./.
====================
He/RB
was/VBD
treated/VBN
with/IN
pemetrexed/JJ
and/CC
cisplatin/NN
for/IN
4/CD
cycles/NNS
,/,
and/CC
his/NN
tumor/NN
shrank/NN
with/IN
the/DT
treatment/NN
./.
====================
But/CC
,/,
his/DT
tumor/NN
rebounded/VBD
,/,
with/IN
a/DT
complaint/JJ
of/IN
dyspnea/NN
and/CC
cough/IN
,/,
4/CD
months/NNS
after/IN
the/DT
completion/NN
of/IN
treatment/NN
./.
====================
After/IN
4/CD
cycles/NNS
of/IN
second-line/JJ
chemotherapy/NN
with/IN
docetaxel/NN
,/,
he/RB
had/VBD
stable/JJ
disease/NN
./.
====================
Even/RB
in/IN
the/DT
case/NN
of/IN
a/DT
dramatic/JJ
response/NN
to/TO
the/DT
first-line/JJ
treatment/NN
,/,
nearly/RB
all/DT
cancers/NNS
rebound/NN
with/IN
various/JJ
relapse-free/JJ
durations/NNS
[/(
30/CD
,/,
34/CD
]/)
./.
====================
The/DT
choice/NN
of/IN
second-line/JJ
treatment/NN
depends/VBZ
on/IN
clinical/JJ
guidelines/NNS
,/,
clinical/JJ
parameters/NNS
,/,
and/CC
clinicians/NNS
'/``
experiences/VBZ
./.
====================
Any/DT
of/IN
the/DT
parameters/NNS
may/MD
not/RB
be/VB
best/JJS
if/IN
a/DT
specific/JJ
patient/NN
's/POS
situation/NN
is/VBZ
not/RB
considered/VBN
./.
====================
We/PRP
do/VBP
not/RB
know/VB
the/DT
exact/JJ
mechanism/NN
of/IN
resistance/NN
to/TO
the/DT
previous/JJ
treatment/NN
and/CC
do/VBP
not/RB
have/VB
any/DT
good/JJ
way/NN
to/TO
assess/VB
the/DT
mechanism/NN
of/IN
resistance/NN
./.
====================
If/IN
cancer/NN
genomics/NNS
is/VBZ
adopted/VBN
in/IN
this/DT
situation/NN
,/,
we/PRP
can/MD
profile/VB
the/DT
tumor/NN
tissue/NN
that/DT
was/VBD
resistant/JJ
to/TO
the/DT
previous/JJ
treatment/NN
./.
====================
The/DT
profile/NN
can/MD
help/VB
clinicians/NNS
decide/VBP
on/IN
a/DT
second-line/JJ
treatment/NN
option/NN
and/CC
improve/VBP
the/DT
individual/JJ
's/POS
outcome/NN
./.
====================
The/DT
resistance/NN
mechanism/NN
could/MD
vary/VB
,/,
depending/VBG
on/IN
multidimensional/JJ
factors/NNS
,/,
such/JJ
as/IN
the/DT
patient/NN
,/,
tumor/NN
biology/NN
,/,
and/CC
previous/JJ
treatment/NN
./.
====================
Especially/RB
,/,
this/DT
situation/NN
should/MD
be/VB
approached/VBN
individually/RB
with/IN
the/DT
concept/NN
of/IN
true/JJ
personalized/VBD
medicine/NN
./.
====================
His/NN
disease/NN
began/VBD
to/TO
grow/VB
again/RB
and/CC
he/RB
refused/VBD
further/RBR
cytotoxic/JJ
chemotherapy/NN
./.
====================
He/RB
was/VBD
in/IN
hospice/NN
care/JJ
and/CC
died/VBD
1/CD
year/NN
after/IN
the/DT
initial/JJ
diagnosis/NN
of/IN
relapse/NN
./.
====================
After/IN
his/NN
death/NN
,/,
his/DT
tumor/NN
was/VBD
sequenced/VBN
by/IN
whole-transcriptome/JJ
analysis/NN
,/,
and/CC
his/NN
tumor/NN
showed/VBD
a/DT
ROS1/NN
translocation/NN
./.
====================
Now/RB
,/,
a/DT
ROS1/NN
inhibitor/NN
is/VBZ
available/JJ
for/IN
this/DT
type/NN
of/IN
cancer/NN
./.
====================
The/DT
median/JJ
overall/JJ
survival/NN
of/IN
metastatic/JJ
lung/NN
cancer/NN
patients/NNS
is/VBZ
1/CD
year/NN
if/IN
there/EX
is/VBZ
no/DT
genetic/JJ
alteration/NN
for/IN
which/WDT
targeted/VBD
agents/NNS
are/VBP
available/JJ
[/(
30/CD
,/,
34/CD
]/)
,/,
as/IN
in/IN
this/DT
case/NN
./.
====================
If/IN
the/DT
patient/NN
has/VBZ
an/DT
EGFR-sensitive/JJ
mutation/NN
or/CC
ALK/NN
translocation/NN
,/,
the/DT
median/JJ
overall/JJ
survival/NN
time/NN
reaches/NNS
2/CD
years/NNS
[/(
35/CD
,/,
36/CD
]/)
./.
====================
A/DT
ROS1/NN
targeting/VBG
agent/NN
,/,
another/DT
example/NN
of/IN
successful/JJ
targeting/VBG
of/IN
oncogene/NN
addiction/NN
,/,
is/VBZ
now/RB
available/JJ
after/IN
his/DT
death/NN
[/(
27/CD
]/)
./.
====================
If/IN
the/DT
ROS1/NN
translocation/NN
was/VBD
known/VBN
for/IN
his/DT
tumor/NN
and/CC
he/RB
was/VBD
treated/VBN
with/IN
a/DT
ROS1/NN
inhibitor/NN
,/,
he/RB
could/MD
have/VB
a/DT
chance/NN
to/TO
live/JJ
an/DT
additional/JJ
one/CD
year/NN
or/CC
more/RBR
./.
====================
Tumors/NNS
have/VBP
very/RB
heterogeneous/JJ
profiles/NNS
[/(
37/CD
,/,
38/CD
]/)
,/,
and/CC
resistant/JJ
tumors/NNS
have/VBP
even/RB
more/RBR
heterogeneous/JJ
ones/NNS
[/(
39/CD
]/)
./.
====================
This/DT
is/VBZ
why/WRB
tumors/NNS
should/MD
ultimately/RB
be/VB
approached/VBN
on/IN
an/DT
individual/JJ
basis/NN
,/,
rather/RB
than/IN
a/DT
population/NN
basis/NN
./.
====================
Now/RB
is/VBZ
the/DT
right/JJ
time/NN
to/TO
think/VB
about/RB
how/WRB
we/PRP
can/MD
use/VB
cancer/NN
genomics/NNS
for/IN
individual/JJ
patients/NNS
./.
====================
There/EX
are/VBP
still/RB
lots/NNS
of/IN
technological/JJ
hurdles-e.g./FW
,/,
functional/JJ
annotation/NN
of/IN
sequencing/NN
results/NNS
,/,
the/DT
way/NN
to/TO
integrate/VB
multi-dimensional/JJ
data/NNS
,/,
and/CC
the/DT
exploration/NN
of/IN
the/DT
clinical/JJ
meaning/VBG
of/IN
sequencing/NN
variants/NNS
for/IN
the/DT
routine/NN
clinical/JJ
usage/NN
of/IN
cancer/NN
genomics/NNS
./.
====================
Defining/VBG
unmet/JJ
clinical/JJ
needs/VBZ
is/VBZ
as/IN
important/JJ
as/IN
overcoming/JJ
technological/JJ
hurdles/NNS
to/TO
maximize/VB
the/DT
benefit/NN
from/IN
cancer/NN
genomics/NNS
./.
====================
Early/JJ
detection/NN
,/,
non-invasive/JJ
molecular/JJ
diagnosis/NN
,/,
risk/NN
prediction/NN
of/IN
relapse/NN
and/CC
tumor-related/JJ
events/NNS
,/,
monitoring/VBG
of/IN
disease/NN
status/NN
,/,
matching/VBG
good/JJ
drugs/NNS
,/,
and/CC
finding/NN
out/IN
personal/JJ
grade/NN
resistance/NN
mechanisms/NNS
are/VBP
good/JJ
examples/NNS
of/IN
unmet/JJ
clinical/JJ
needs/VBZ
that/DT
should/MD
be/VB
solved/VBN
with/IN
cancer/NN
genomics/NNS
./.
====================
It/PRP
would/MD
speed/RB
up/IN
and/CC
optimize/VBP
the/DT
application/NN
of/IN
genomics/NNS
to/TO
cancer/NN
clinics/NNS
if/IN
cancer/NN
biologists/NNS
,/,
bioinformaticians/NNS
,/,
and/CC
cancer/NN
clinicians/NNS
cooperate/VBP
towards/IN
one/CD
goal/NN
of/IN
achieving/VBG
it/PRP
./.
====================
